GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Filgotinib
Drug: PTM filgotinib

First Posted Date: 2016-09-26

Last Posted Date: 2021-04-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 1351

Registration Number: NCT02914522

Locations: 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇷🇺
State Healthcare Institution "Regional Clinical Hospital", Saratov, Russian Federation
🇷🇺
State Autonomous Health Institution of the Tyumen Region "Multidisciplinary Consultative and Diagnostic Center", Tyumen, Russian Federation

and more 339 locations

Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: Sofosbuvir

First Posted Date: 2016-09-20

Last Posted Date: 2021-12-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 2033

Registration Number: NCT02907996

Locations: 🇰🇷
Yonsei University Wonju Severance Christian Hospital, Wonju, Gangwon-do, Korea, Republic of
🇰🇷
SoonChunHyang University Cheonan Hospital, Cheonan, Korea, Republic of
🇰🇷
Daegu Catholic University Medical Center, Daegu, Korea, Republic of

and more 68 locations

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Nonalcoholic Steatohepatitis (NASH)

Interventions: Drug: Firsocostat
Drug: Fenofibrate

First Posted Date: 2016-09-07

Last Posted Date: 2020-12-17

Lead Sponsor: Gilead Sciences

Target Recruit Count: 74

Registration Number: NCT02891408

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Filgotinib
Drug: Placebo to match filgotinib
Drug: Adalimumab
Drug: Placebo to match adalimumab
Drug: MTX

First Posted Date: 2016-09-07

Last Posted Date: 2021-06-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 1759

Registration Number: NCT02889796

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Filgotinib
Drug: Placebo to match filgotinib
Drug: MTX
Drug: Placebo to match MTX

First Posted Date: 2016-09-01

Last Posted Date: 2021-06-01

Lead Sponsor: Gilead Sciences

Target Recruit Count: 1252

Registration Number: NCT02886728

Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: GS-9876
Drug: GS-9876 placebo
Drug: Filgotinib
Drug: Filgotinib placebo
Drug: Methotrexate

First Posted Date: 2016-08-31

Last Posted Date: 2018-09-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 83

Registration Number: NCT02885181

Locations: 🇺🇸
Center For Arthritis and Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸
Albuquerque Center For Rheumatology, Albuquerque, New Mexico, United States

and more 16 locations

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

Phase 2

Active, not recruiting

Conditions: HIV-1 Infection

Interventions: Drug: B/F/TAF (Adult Strength)
Drug: B/F/TAF (Low Dose)
Drug: B/F/TAF (TOS)

First Posted Date: 2016-08-26

Last Posted Date: 2024-10-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 177

Registration Number: NCT02881320

Locations: 🇺🇸
Children's National Health System, Washington, District of Columbia, United States
🇺🇸
Midway Immunology and Research Center, Fort Pierce, Florida, United States
🇺🇸
University of Florida Health, Gainesville, Florida, United States

and more 22 locations

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

Phase 1

Completed

Conditions: PD Effects of GS-0976 (NDI-010976) on Fractional DNL

Interventions: Drug: GS-0976
Drug: Placebo
Other: 1-13C acetate
Other: Fructose solution

First Posted Date: 2016-08-24

Last Posted Date: 2016-08-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT02876796

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Filgotinib
Drug: Placebo to match filgotinib
Drug: csDMARDs

First Posted Date: 2016-08-22

Last Posted Date: 2021-05-13

Lead Sponsor: Gilead Sciences

Target Recruit Count: 449

Registration Number: NCT02873936

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF

First Posted Date: 2016-08-16

Last Posted Date: 2020-03-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 19

Registration Number: NCT02868242

Locations: 🇪🇬
National Cancer Institute, Cairo University, Cairo, Egypt

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy